Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

被引：18

作者：

Bookman, MA

Greer, BE

Ozols, RF

机构：

[1] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA

[2] Univ Washington, Sch Med, Div Gynecol Oncol, Seattle, WA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2003年 / 13卷

关键词：

carboplatin; ovarian cancer; paclitaxel; second-look;

D O I：

10.1111/j.1525-1438.2003.13362.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multi-armed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

引用

收藏

页码：149 / 155

页数：7

相关论文

共 12 条

[1] Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group [J].

Bookman, MA ;

McGuire, WP ;

Kilpatrick, D ;

Keenan, E ;

Hogan, WM ;

Johnson, SW ;

ODwyer, P ;

Rowinsky, E ;

Gallion, HH ;

Ozols, RF .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1895-1902

[2] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].

Bookman, MA ;

Darcy, KM ;

Clarke-Pearson, D ;

Boothby, RA ;

Horowitz, IR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290

[3]

DUBOIS A, 1999, P AN M AM SOC CLIN, V18, pA1374

[4] The effect of body mass index on clinical/pathol ogic features, surgical morbidity, and outcome in patients with endometrial cancer [J].

Everett, E ;

Tamimi, H ;

Greer, B ;

Swisher, E ;

Paley, P ;

Mandel, L ;

Goff, B .

GYNECOLOGIC ONCOLOGY, 2003, 90 (01) :150-157

[5] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].

McGuire, WP ;

Hoskins, WJ ;

Brady, MF ;

Kucera, PR ;

Partridge, EE ;

Look, KY ;

ClarkePearson, DL ;

Davidson, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6

[6] Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study [J].

Muggia, FM ;

Braly, PS ;

Brady, MF ;

Sutton, G ;

Niemann, TH ;

Lentz, SL ;

Alvarez, RD ;

Kucera, PR ;

Small, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :106-115

[7] Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer [J].

Neijt, JP ;

Engelholm, SA ;

Tuxen, MK ;

Sorensen, PG ;

Hansen, M ;

Sessa, C ;

de Swart, CAM ;

Hirsch, FR ;

Lund, B ;

van Houwelingen, HC .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3084-3092

[8] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].

Ozols, RF ;

Bundy, BN ;

Greer, BE ;

Fowler, JM ;

Clarke-Pearson, D ;

Burger, RA ;

Mannel, RS ;

DeGeest, K ;

Hartenbach, EM ;

Baergen, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200

[9]

OZOLS RF, 1999, P AN M AM SOC CLIN, V18, P1373

[10]

Parmar MKB, 2002, LANCET, V360, P505